The transaction is valued at an enterprise value of $250 million (₹21,850 crore) on a cash-free, debt-free basis, including normalised working capital levels. Shares of Aurobindo Pharma Ltd ended at ₹1,153.50, down by ₹4.60, or 0.40%, on the BSE.
The transaction is valued at an enterprise value of $250 million (₹21,850 crore) on a cash-free, debt-free basis, including normalised working capital levels. Shares of Aurobindo Pharma Ltd ended at ₹1,153.50, down by ₹4.60, or 0.40%, on the BSE.